Something to be done: treating HIV/AIDS. River Path Associates.
Largely because of disparities in access to drug treatment and care, AIDS morbidity and mortality have fallen in the developed world but continue to rise among developing countries. Achieving more equitable access to AIDS drugs is hindered by high drug prices, technical complexities related to the provision of health care, and conflict among stakeholders. Recognition that health is vital to the prospects of the emerging global society must be combined with new mechanisms to help all stakeholders work together cooperatively. Tiered drugs pricing should be coupled with investment in health services. An independent "Global Task Force," able to act as an "active think tank," could build consensus about the way forward.
Bloom
D E
DE
Department of Population and International Health, School of Public Health, Harvard University, Boston, MA 02115, USA. dbloom@hsph.harvard.edu
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003695:Delivery of Health Care; D003906:Developing Countries; D016527:Drug Costs; D004345:Drug Industry; D004363:Drug Utilization; D005378:Financial Support; D014943:Global Health; D015658:HIV Infections / Q000188:drug therapy*; D006291:Health Policy; D006801:Humans; D007391:International Cooperation; D014481:United States
D019380:Anti-HIV Agents